author-photo

Brendan Rooney

Janssen Pharmaceutica

19

Papers

374

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Apalutamide and Overall Survival in Prostate Cancer

2020 European Urology
Show All
- Source
- Cite
- Save
Citations (49)
Efficacy and safety of apalutamide in Japanese patients with non-metastatic castration-resistant prostate cancer: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 study

2020 Prostate international
Show All
- Source
- Cite
- Save
Citations (4)
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

2018 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (12)
PD10-11 PROSTATE-SPECIFIC ANTIGEN (PSA) OUTCOMES IN PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) TREATED WITH APALUTAMIDE (APA): RESULTS FROM PHASE 3 SPARTAN STUDY

2018 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (1)
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

2017 Haematologica
Show All
- Source
- Cite
- Save
Citations (2)
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

2015 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (253)
PHASE 3 STUDY OF FRONTLINE RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE PLUS VINCRISTINE (R-CHOP) OR BORTEZOMIB (VR-CAP) IN TRANSPLANTATION-UNSUITABLE MANTLE CELL LYMPHOMA (MCL) PATIENTS

2014 Haematologica
Show All
- Source
- Cite
- Save
Citations (0)
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

2014 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Efficacy and Safety of Bortezomib Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in Japanese Patients (Pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Considered for Transplantation Enrolled in the International, Randomized, Phase 3 LYM-3002 Study (NCT00722137)

2014 Blood
Show All
- Source
- Cite
- Save
Citations (0)